Shopping Cart
- Remove All
- Your shopping cart is currently empty
MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $55 | In Stock | |
5 mg | $123 | In Stock | |
10 mg | $196 | In Stock | |
25 mg | $392 | In Stock | |
50 mg | $629 | In Stock | |
100 mg | $886 | In Stock | |
500 mg | $1,770 | In Stock |
Description | MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide. |
Targets&IC50 | PPARγ:18.25 μM |
In vivo | Diabetic db/db and MS-NASH mice are treated with MSDC-0602K via oral gavage, Liraglutide via s.c. injection, or a combination of MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis. Animal Model: Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice [1]. Dosage: 30 mg/kg MSDC-0602K and 0.2 mg/kg Liraglutide. Administration: MSDC-0602K gavage daily, Liraglutide s.c. every other day, or combined MSDC-0602K + Liraglutide. Result: MSDC-0602K alone corrected glycemia and reduced insulinemia, while the combination with Liraglutide significantly improved glucose tolerance and liver histology[1]. |
Alias | MSDC-0602K, Azemiglitazone potassium |
Molecular Weight | 409.5 |
Formula | C19H16KNO5S |
Cas No. | 1314533-27-1 |
Smiles | COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)[N-]C(=O)S3.[K+] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (122.1 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.